Also found in: Medical.
CABPCommunity-Acquired Bacterial Pneumonia
CaBPCalcium Binding Protein
CABPCanadian Alliance of British Pensioners (Toronto, Canada)
CABPCameron Ashley Building Products, Inc. (Dallas, TX)
CABPCoalition Air Battle Planning
CABPCarotid Artery Blood Pressure
CABPCertificate of the Arab Board of Pediatrics
References in periodicals archive ?
TEFLARO is also indicated for the treatment of CABP caused by susceptible bacterial isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli.
A procedure plagued by complication rates, figures show that post-surgery complications have been reported in as high as 15 to 25 per cent of cases of CABP.
circa 1898] in Folder 22: Recommendations for Charles Austin Beard, DC 10, CABP.
In fact, nearly one-quarter of surveyed physicians indicate prescribing ceftaroline for CABP due to MRSA, and about 10 percent have used the drug for NP in the past 12 months.
The Pharmacor advisory service entitled Community-Acquired Bacterial Pneumonia finds that the CABP antibiotic market will experience modest growth over the next decade, increasing from approximately $1 billion in 2011 to more than $1.
FDA in October 2010 for the treatment of adults with CABP and ABSSSI due to designated susceptible pathogens.
Nabriva is establishing its US office and clinical development team in Philadelphia and is focussed on advancing lefamulin to phase 3 trials, for an initial indication in CABP.
Mark Leuchtenberger, Chief Executive Officer of Rib-X said, "The need for antibiotics that safely treat a broader spectrum of infections, not to mention those which have shown resistance to linezolid, is growing and radezolid has thus far succeeded in addressing a diverse set of challenges in ABSSSI and CABP.
What factors are driving the market for CABP therapies?
In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, radezolid's key competitor in the CABP drug market through 2020 will be Pfizer's Zyvox.
Food and Drug Administration for the phase 3 trials planned in ABSSSI and CABP.
The goal of Solitaire-IV is to provide evidence of safety and efficacy of an IV-to-oral step down regimen that we believe will provide clinicians and their patients a better therapeutic option to treat CABP," said Prabhavathi Fernandes, Ph.